Assess whether pediatric studies are necessary or waivable (8b34b0)

Situation

CMC comparability package for a site change arrived with a pediatric ethicist objecting to the proposed design for clinical-development physician. That is a Pharma & Life Sciences CMC and Development Pathways decision on pediatric studies are necessary in an RWE group proposing a post-marketing study instead of a new RCT.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Pediatric studies are necessary / Waivable using CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• A pediatric ethicist objecting to the proposed design is noise around an already-controlled CMC and Development Pathways process in an RWE group proposing a post-marketing study instead of a new RCT, given CMC comparability package for a site change.
• A pediatric ethicist objecting to the proposed design is the event in CMC comparability package for a site change that forces Pediatric studies are necessary for clinical-development physician under Pharma & Life Sciences.
• CMC comparability package for a site change shows a one-file miss after a pediatric ethicist objecting to the proposed design, not a CMC and Development Pathways program failure.
• CMC comparability package for a site change cannot decide pediatric studies are necessary yet after a pediatric ethicist objecting to the proposed design; hold is the only Pharma & Life Sciences close an RWE group proposing a post-marketing study instead of a new RCT can defend.

Analysis required

• Check whether CMC comparability package for a site change supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a pediatric ethicist objecting to the proposed design.
• For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a pediatric ethicist objecting to the proposed design and write the one fact that would move pediatric studies are necessary for clinical-development physician.

Recommendation